111 related articles for article (PubMed ID: 20162752)
41. Bisphosphonate osteonecrosis of the jaws in cancer patients.
Kyrgidis A; Andreadis C
Breast; 2009 Oct; 18(5):335. PubMed ID: 19783147
[No Abstract] [Full Text] [Related]
42. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients.
Bisdas S; Chambron Pinho N; Smolarz A; Sader R; Vogl TJ; Mack MG
Clin Radiol; 2008 Jan; 63(1):71-7. PubMed ID: 18068792
[TBL] [Abstract][Full Text] [Related]
43. A cautious approach.
Girgis S
Br Dent J; 2010 May; 208(10):439-40. PubMed ID: 20489743
[No Abstract] [Full Text] [Related]
44. Specialists play down risk of jaw condition.
Stassen LF
J Ir Dent Assoc; 2008; 54(4):153. PubMed ID: 18780680
[No Abstract] [Full Text] [Related]
45. Osteonecrosis of the jaws: maxillofacial recommendations for bisphosphonate prescribers.
Landis BN; Dojcinovic I; Richter M; Hugentobler M
J Intern Med; 2007 Jan; 261(1):101-2. PubMed ID: 17222173
[No Abstract] [Full Text] [Related]
46. Bisphosphonates and their impact on patient treatment.
Kurtzman GM; Silverstein LH; Peden J
Pract Proced Aesthet Dent; 2006 Jun; 18(5):297-8. PubMed ID: 16903540
[No Abstract] [Full Text] [Related]
47. Avascular osteonecrosis of the jaw as a side effect of bisphosphonate treatment.
Bamias A; Terpos E; Dimopoulos MA
Onkologie; 2010; 33(6):288-9. PubMed ID: 20523090
[No Abstract] [Full Text] [Related]
48. Do Fosamax-type drugs increase the risk of osteonecrosis of the jaw for patients receiving dental implants?
Wynn RL
Gen Dent; 2008; 56(5):410-1. PubMed ID: 18683394
[No Abstract] [Full Text] [Related]
49. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
[No Abstract] [Full Text] [Related]
50. Bisphosphonates and oral health.
Ritter AV; Padilla R
J Esthet Restor Dent; 2008; 20(1):74-5. PubMed ID: 18237344
[No Abstract] [Full Text] [Related]
51. Bisphosphonate-related osteonecrosis of the jaw.
Feller L; Wood NH; Khammissa RA; Chikte UM; Bouckaert M; Lemmer J
SADJ; 2011 Feb; 66(1):30-2. PubMed ID: 21510174
[TBL] [Abstract][Full Text] [Related]
52. Bisphosphonates, osteonecrosis of the jaw, and dental treatment recommendations.
Radfar L; Masood F
J Okla Dent Assoc; 2008; 99(7):28-9. PubMed ID: 18595621
[TBL] [Abstract][Full Text] [Related]
53. Standard protocols.
Kini G
Br Dent J; 2007 Oct; 203(8):440. PubMed ID: 17965662
[No Abstract] [Full Text] [Related]
54. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
55. Horizons: the 2009 table clinics.
Thumbigeremath V
Northwest Dent; 2009; 88(3):33-4, 87. PubMed ID: 19691205
[No Abstract] [Full Text] [Related]
56. Bisphosphonate associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Fugazzotto PA; Lightfoot S
J Mass Dent Soc; 2006; 55(2):5. PubMed ID: 16937899
[No Abstract] [Full Text] [Related]
57. Bisphosphonate-induced osteonecrosis of the jaws: a challenge, a responsibility, and an opportunity.
Marx RE
Int J Periodontics Restorative Dent; 2008 Feb; 28(1):5-6. PubMed ID: 18351197
[No Abstract] [Full Text] [Related]
58. Bisphosphonate induced osteonecrosis of the jaws: unravelling uncertainty in disease causality.
Kelleher FC; McKenna M; Collins C; Brady G; Collins I; Crown J
Acta Oncol; 2007; 46(5):702-4. PubMed ID: 17562449
[No Abstract] [Full Text] [Related]
59. Slumbering time-bomb.
Dean F
Br Dent J; 2006 Sep; 201(5):249. PubMed ID: 16960582
[No Abstract] [Full Text] [Related]
60. Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease.
McMahon RE; Bouquot JE; Glueck CJ; Griep JA; Adams WR; Spolnik KJ; Deardorf KA
J Oral Maxillofac Surg; 2007 Sep; 65(9):1899-900. PubMed ID: 17719423
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
